Education
About Us
Working with TipRanks
Follow Us
MBX Biosciences, Inc. (MBX)
:MBX
MBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.81 - $27.50
Previous CloseN/A
Volume52.29K
Average Volume (3M)442.41K
Market Cap
$420.93M
Enterprise Value$157.38M
Total Cash (Recent Filing)$240.79M
Total Debt (Recent Filing)$130.00K
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Nov 06, 2025EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding33,593,864
10 Day Avg. Volume509,535
30 Day Avg. Volume442,414
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$40.00Price Target Upside255.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial StabilityMBX has a cash runway into mid-2027, providing financial support for its operations and further development of its pipeline, including MBX 4291.
Market PotentialMBX 4291 has blockbuster potential in the obesity market, with a unique once-monthly dosing differentiation compared to other treatments.
Product DifferentiationCanvuparatide offers significant global peak potential due to its differentiating weekly dosing in the emerging parathyroid hormone replacement market for hypoparathyroidism.
Bears Say
Investor SentimentStock traded down due to investor profit-taking and confusion around PD serum calcium levels in healthy volunteers.
MBX Biosciences, Inc. News
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $4.81 and its highest was $27.50 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $420.93M.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
MBX Biosciences, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 84 days.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.735 by $0.155.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate is -0.71.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 33,593,864 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.735. Following the earnings report the stock price went down -4.627%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
MBX Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.00 (255.24% Upside)
$40.00 (255.24% Upside)
Blogger Sentiment
Bullish
MBX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 290.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 15.9%
Last 30 Days ▲ 22.4%
Last 30 Days ▲ 22.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-56.28%
Trailing 12-Months
Asset Growth
268.18%
Trailing 12-Months
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Stock 12 Month Forecast
Average Price Target
$40.00
▲(255.24% Upside)
Technical Analysis
Abeona Therapeutics
―
Solid Biosciences
―
iTeos Therapeutics
―
Olema Pharmaceuticals
―
enGene Holdings
―
Ownership Overview
Currently, No data available
---